NCT02013778TerminatedPhase 1
Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
Abramson Cancer Center at Penn Medicine1 site in 1 country8 target enrollmentStarted: November 2013Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Number of Participants With Adverse Events
Study Overview
Brief Summary
Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient capable of giving informed consent
- •Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
- •Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
- •Age 18 years old
- •Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
- •Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
- •Child-Turcotte-Pugh Classification A or B
- •Eastern Clinical Oncology Group performance status 0 or1.
Exclusion Criteria
- •Prior TACE
- •Active GI hemorrhage within 2 weeks of study enrollment
- •Ascites refractory to medical therapy
- •Contraindication to receiving HCQ or TACE
- •Unilobar HCC
- •Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
- •Women who are pregnant
- •Participation in another concurrent treatment protocol
Arms & Interventions
TACE + HCQ
Experimental
Subjects will receive HCQ plus standard of care TACE.
Intervention: HCQ (Drug)
Outcomes
Primary Outcomes
Number of Participants With Adverse Events
Time Frame: 1 year
Adverse Events graded according to the Common Terminology Criteria of Adverse Events (CTCAE) version 4.0
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Pharmacokinetic Profile of CKD-581Multiple MyelomaLymphomaNCT01580371Chong Kun Dang Pharmaceutical39
Completed
Phase 1
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid CancersUnspecified Adult Solid Tumor, Protocol SpecificNCT01560325Chong Kun Dang Pharmaceutical21
Completed
Phase 1
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid CancersUnspecified Adult Solid Tumor, Protocol SpecificNCT01028859Chong Kun Dang Pharmaceutical30
Completed
Phase 1
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid TumorsLiver CancerNCT00374660Eisai Inc.63
Completed
Phase 1
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36